CRISPR Therapeutics AG CRSP
Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex.
We have established a portfolio of therapeutic programs spanning four core franchises: hemoglobinopathies, in vivo, CAR T approaches and regenerative medicine. Depending on the program, we take either an ex vivo approach, in which we edit cells outside of the human body before administering them to the patient, or an in vivo editing approach, where we deliver the CRISPR-based therapeutic directly to target cells within the human body.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $37.3M | $371.2M | $1.2M | $915.0M | $719.0K | $289.6M | $3.1M | $41.0M | $5.2M |
| R&D | $284.8M | $310.2M | $387.3M | $461.6M | $340.6M | $221.4M | $179.4M | $113.8M | $69.8M | $42.2M |
| SG&A | $73.5M | $73.0M | $76.2M | $102.5M | $99.7M | $85.7M | $63.5M | $48.3M | $35.8M | $31.1M |
| Total operating expenses | $668.1M | $503.9M | $593.7M | $674.4M | $541.4M | $355.2M | $242.8M | $162.1M | $105.6M | $73.3M |
| Operating income | -$664.6M | -$466.6M | -$222.5M | -$673.2M | $373.5M | -$354.4M | $46.7M | -$158.9M | -$64.6M | -$68.1M |
| Pre-tax income | -$578.0M | -$362.7M | -$150.7M | -$650.5M | $379.5M | -$348.1M | $67.3M | -$164.4M | -$66.6M | -$22.7M |
| Income tax | $3.6M | $3.6M | $2.9M | $325.0K | $1.9M | $809.0K | $448.0K | $553.0K | $1.7M | $484.0K |
| Net income | -$581.6M | -$366.3M | -$153.6M | -$650.2M | $377.7M | -$348.9M | $66.9M | -$165.0M | -$68.4M | -$23.2M |
| EPS, basic | -6.47 | -4.34 | -1.94 | -8.36 | 4.97 | -5.29 | 1.23 | -3.44 | -1.71 | — |
| EPS, diluted | -6.47 | -4.34 | -1.94 | -8.36 | 4.70 | -5.29 | 1.17 | -3.44 | -1.71 | -1.89 |
| Shares, diluted (wtd. avg.) | $89.9M | $84.4M | $79.2M | $77.7M | $80.4M | $65.9M | $56.9M | $48.0M | $40.1M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $347.6M | $298.3M | $389.5M | $211.9M | $923.0M | $1.17B | $943.8M | $456.6M | $239.8M | $315.5M |
| Short-term investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $521.7M | $0 | — | — | — |
| Receivables | $0 | $25.0M | $200.0M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $2.6M | $3.2M |
| Total current assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $987.5M | $466.4M | $248.4M | $320.2M |
| Property, plant and equipment | $115.9M | $134.1M | $151.9M | $163.6M | $137.6M | $42.2M | $31.3M | $18.5M | $18.9M | $21.0M |
| Other intangibles | — | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K |
| Total assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489.0M | $271.3M | $345.0M |
| Accounts payable | $11.1M | $14.7M | $38.1M | $27.4M | $14.8M | $9.1M | $5.9M | $5.1M | $1.6M | $4.6M |
| Total current liabilities | $149.1M | $87.8M | $108.8M | $121.1M | $119.9M | $94.3M | $57.1M | $27.7M | $14.5M | $22.0M |
| Total liabilities | $343.4M | $310.0M | $346.8M | $367.6M | $352.4M | $163.7M | $127.3M | $96.8M | $83.5M | $112.1M |
| Retained earnings | -$1.95B | -$1.37B | -$999.7M | -$846.1M | -$195.9M | -$573.6M | -$224.7M | -$291.6M | -$125.4M | -$57.1M |
| Total equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939.4M | $392.2M | $187.8M | $232.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$345.0M | -$142.8M | -$260.4M | -$495.7M | $539.0M | -$238.4M | $56.7M | -$96.2M | -$70.1M | -$52.9M |
| Depreciation and amortisation | $19.5M | $19.3M | $19.8M | $24.2M | $18.0M | $9.2M | $4.7M | $3.5M | $3.0M | $925.0K |
| Stock-based compensation | $72.5M | $86.6M | $81.0M | $97.9M | $102.4M | $66.0M | $44.1M | $35.0M | $18.9M | $10.8M |
| Capital expenditure | $914.0K | $1.9M | $9.5M | $37.2M | $81.7M | $18.4M | $6.7M | $2.8M | $7.8M | $3.0M |
| Investing cash flow | -$31.8M | -$280.5M | $374.6M | -$258.7M | -$1.04B | -$541.2M | $1.3M | -$2.8M | -$8.3M | $31.9M |
| Financing cash flow | $426.0M | $332.0M | $62.7M | $38.6M | $250.9M | $1.02B | $431.0M | $315.9M | $2.6M | $183.2M |
| Buybacks | — | — | — | — | — | — | — | $57.0K | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-165158.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |